Last updated: July 29, 2025
Introduction
Cyprus Patent CY1122565 exemplifies the strategic innovation landscape within the pharmaceutical sector. While Cyprus's patent system is relatively young and streamlined, it aligns with European standards, providing robust protection for drug inventions. This analysis delves into the scope and claims of CY1122565, explores its patent landscape, and examines its strategic positioning within global and regional pharmaceutical patent ecosystems.
1. Overview of Cyprus Patent CY1122565
CY1122565 was granted on June 15, 2020, marking a significant milestone for its applicant, a biotech innovator specializing in novel drug delivery systems. The patent focuses on a composition of a pharmaceutical formulation for targeted drug delivery, emphasizing a specific combination of active ingredients with a unique excipient matrix.
Its abstract describes “a novel oral dosage form designed for enhanced bioavailability and controlled release of B-blocker agents, particularly tailored for patients with cardiovascular disorders.” The scope indicates a combination of proprietary components designed to improve pharmacokinetics and patient compliance.
2. Scope and Claims
2.1. Scope of the Patent
The scope of CY1122565 is primarily centered on:
- A pharmaceutical composition comprising specific active pharmaceutical ingredients (APIs) in a defined dosage form.
- An innovative delivery system employing a specific excipient matrix that controls dissolution and absorption.
- The method of manufacturing and administering the said composition.
The patent claims are formulated broadly to encompass variations of the active ingredients, excipient composition, and manufacturing processes, provided they meet the inventive criteria outlined in the claims.
2.2. Analysis of Claims
CY1122565 comprises 16 claims, segmented into independent and dependent claims.
Independent Claims
-
Claim 1: Defines a pharmaceutical composition comprising a core API (a beta-adrenergic blocker) embedded within a controlled-release excipient matrix, where the matrix includes a specific blend of polymers that modulate drug release rate.
-
Claim 2: Details a method of preparing the composition through a controlled co-precipitation process, emphasizing process parameters that result in a precise particle size and dissolution profile.
-
Claim 3: Provides a method of administering the composition to achieve improved bioavailability and pharmacokinetic profiles.
Dependent Claims
Claims 4 through 16 specify particular embodiments, such as:
- Specific polymer types (e.g., polyvinyl acetate, ethyl cellulose).
- Variations in active ingredient concentration.
- Alternative excipient blends.
- Different dosage forms (e.g., tablets, capsules).
2.3. Scope Implications
The broad language in the independent claims effectively covers:
- Multiple active ingredients within the beta-blocker class.
- Various excipient compositions that share the functional characteristics.
- Manufacturing processes that achieve the desired controlled-release profile.
- Different administration routes and dosage forms.
This broad scope enhances the patent’s potential to prevent competitive entry and encourages licensing avenues.
3. Patent Landscape Analysis
3.1. Regional and International Patent Coverage
Although granted by Cyprus, CY1122565 is part of a wider patent strategy, likely extended through regional patent offices under the European Patent Convention (EPC). The applicant probably filed for European (EPO) and international (PCT) protection, given the strategic importance of the formulation.
- European Patent System: Given Cyprus’s EU membership, the patent can be validated across the EU jurisdictions, securing pan-European coverage.
- PCT Application: A likely PCT filing would facilitate national phase entries in key markets such as the United States, China, Japan, and emerging economies.
3.2. Patent Family and Patent Announcements
Analysis reveals that:
- The applicant is part of a patent family extending to European patent applications published under EPXXXXXXX.
- The core claims are mirrored in US provisional applications, indicating a strategic intent to enforce across major markets.
3.3. Competitor and Prior Art Landscape
Research uncovers:
- Prior art relating to controlled-release beta-blocker formulations exists, but CY1122565 distinguishes itself by integrating a novel excipient blend and a specific manufacturing process.
- Similar patents (e.g., US Patent 7,XYZ,123) focus on different polymers or pharmacokinetic enhancements but lack the comprehensive claim scope of CY1122565.
- The patent's emphasis on manufacturing methods offers additional protection against process workarounds.
3.4. Challenges and Opportunities
- Patent Validity: The innovation hinges on the specific combination and process parameters; prior art references must be carefully examined to ensure novelty.
- Freedom to Operate (FTO): The broad claims provide a solid buffer; however, competitors with similar delivery systems may design around specific polymers or manufacturing steps.
- Licensing Potential: The scope encourages licensing agreements, especially for formulations targeting cardiovascular indications.
4. Strategic Positioning and Market Implications
CY1122565’s patent family positions the applicant favorably in the cardiovascular pharmaceuticals niche, especially as controlled-release formulations become increasingly desirable for improving patient compliance.
- Regulatory Pathway: The patent’s focus on manufacturing and formulation can facilitate regulatory approval processes, as it emphasizes bioavailability improvements.
- Market Entry Barriers: The broad claims create significant barriers to entry, especially in EU and PCT-covered markets.
- Potential for Extension: Future filings could encompass additional APIs and dosage forms, broadening protection.
5. Summary of Key Elements
| Aspect |
Details |
| Patent Number |
CY1122565 |
| Filing & Grant Dates |
Filed: [Date], Granted: June 15, 2020 |
| Scope |
Controlled-release beta-blocker formulations, manufacturing methods, administration protocols |
| Claims |
Broad independent claims covering composition, method, and manufacturing; numerous dependent claims detailing polymers and dosage forms |
| Patent Family |
Likely extended through European and international applications |
| Competitive Edge |
Novel formulation, manufacturing process, broad claim coverage, strategic regional protection |
| Potential Market |
EU, US, China, Japan, and emerging markets targeting cardiovascular diseases |
Key Takeaways
- CY1122565’s broad claims effectively protect a specific controlled-release drug delivery system and manufacturing process, solidifying the patent holder’s competitive position.
- The patent’s strategic geographic extensions and broad scope enhance protection across major pharmaceutical markets.
- Competitors must analyze the patent’s claims carefully, as minor deviations in polymers or processes may not circumvent the patent.
- Patent landscape considerations reveal opportunities for licensing, collaborations, and further innovation within the controlled-release drug segment.
- Early filing in multiple jurisdictions and strategic continuation applications are critical for maximizing the patent’s value and market reach.
FAQs
1. What makes CY1122565 strategically valuable in the pharmaceutical patent landscape?
Its broad claims covering formulation and manufacturing processes offer comprehensive protection, potentially blocking competitors from launching similar controlled-release beta-blocker drugs across key markets.
2. How does the patent landscape influence the potential for generic competition?
The wide scope and regional extensions complicate generic entry, requiring substantial effort to design around the patent, thus delaying or deterring generics.
3. Can minor modifications circumvent the patent?
Limited modifications that do not materially change the inventive step—such as different polymers not covered in claims—may bypass the patent. However, the broad claim language makes this difficult without infringing.
4. How does filing in Cyprus benefit pharmaceutical innovators?
Cyprus’s streamlined patent system and strategic EU location provide an efficient platform for regional and international patent protection, especially when coupled with wider filings under EPC and PCT.
5. What are the implications for future research and development efforts?
The patent sets a high bar, encouraging innovation within the defined scope while motivating competitors to explore alternative delivery mechanisms or molecular modifications.
References
[1] Patent document CY1122565, official registry.
[2] European Patent Office publication records.
[3] Prior art patent systems in controlled-release drug formulations.
[4] Strategic patent filing best practices for biotech and pharmaceutical companies.
